Incorporating Newer ASMs in Pediatric Patients With Dravet Syndrome

Panelists discuss how despite newer medications such as cannabidiol, stiripentol, and fenfluramine being available for several years and recommended as first-line therapies, claims data reveals that only 7% to 25% of patients with newly diagnosed Dravet syndrome receive these treatments, with many clinicians still defaulting to older, less effective medications due to lack of practical guidance on dosing and titration protocols for the newer therapies.